Literature DB >> 14628192

Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain.

M J Hurley1, D C Mash, P Jenner.   

Abstract

Reverse transcription polymerase chain reaction (RT-PCR) was used to examine the expression of the cannabinoid CB(1) receptor mRNA in post-mortem brain tissue obtained from normal subjects and patients dying with Parkinson's disease. CB(1) receptor mRNA was detected in striatal (nucleus accumbens, caudate nucleus and putamen) and extrastriatal (globus pallidus, substantia nigra) brain regions. In parkinsonian tissue the level of CB(1) receptor mRNA was decreased in the caudate nucleus, anterior dorsal putamen and external segment of the globus pallidus, but remained unchanged in the other brain areas examined. These results show that CB(1) receptor mRNA expression was altered in Parkinson's disease (though the effects of drug treatment can not be ruled out) and indicate that cannabinoid CB(1) receptor mRNA expression was affected by alterations in dopaminergic systems.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14628192     DOI: 10.1007/s00702-003-0033-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  25 in total

Review 1.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

Review 2.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

3.  The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.

Authors:  Szabolcs Farkas; Katalin Nagy; Zhisheng Jia; Tibor Harkany; Miklós Palkovits; Sean R Donohou; Victor W Pike; Christer Halldin; Domokos Máthé; László Csiba; Balázs Gulyás
Journal:  Brain Res Bull       Date:  2012-03-07       Impact factor: 4.077

Review 4.  The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Authors:  Emma L Scotter; Mary E Abood; Michelle Glass
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis.

Authors:  Attila Köfalvi; Ricardo J Rodrigues; Catherine Ledent; Ken Mackie; E Sylvester Vizi; Rodrigo A Cunha; Beáta Sperlágh
Journal:  J Neurosci       Date:  2005-03-16       Impact factor: 6.167

6.  Cannabinoid CB1 and CB2 Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson's Disease.

Authors:  Francisco Navarrete; M Salud García-Gutiérrez; Auxiliadora Aracil-Fernández; José L Lanciego; Jorge Manzanares
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 7.  The therapeutic potential of cannabinoids for movement disorders.

Authors:  Benzi Kluger; Piera Triolo; Wallace Jones; Joseph Jankovic
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

8.  Cannabinoid modulation of limbic forebrain noradrenergic circuitry.

Authors:  Ana F Carvalho; Kenneth Mackie; Elisabeth J Van Bockstaele
Journal:  Eur J Neurosci       Date:  2010-01-13       Impact factor: 3.386

9.  Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat.

Authors:  Sinéad Walsh; Katarzyna Mnich; Ken Mackie; Adrienne M Gorman; David P Finn; Eilís Dowd
Journal:  Brain Res Bull       Date:  2010-01-25       Impact factor: 4.077

Review 10.  The dynamic nature of type 1 cannabinoid receptor (CB(1) ) gene transcription.

Authors:  R B Laprairie; M E M Kelly; E M Denovan-Wright
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.